StoxWockhardt vs Rubicon Research: share price & financials comparison
NSE: WOCKPHARMA vs RUBICON · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Wockhardt vs Rubicon Research at a glance
Wockhardt (WOCKPHARMA) has a market capitalisation of ₹31,541 Cr, against ₹27,466 Cr for Rubicon Research (RUBICON). Over the past year Rubicon Research has returned +176.3%, compared with +49.0% for Wockhardt. On valuation, Wockhardt trades at a lower P/E of 76.9 versus 84.6. Rubicon Research earns a higher return on equity (22.9% vs 7.9%). Wockhardt comes out ahead on valuation. Rubicon Research comes out ahead on size, profitability, growth, financial health, momentum and technicals. Across the scored metrics below, Wockhardt leads on 2 and Rubicon Research on 11. On StoxGud's 10-point checklist, Wockhardt scores 7/10 and Rubicon Research scores 8/10.
| Metric | Wockhardt | Rubicon Research |
|---|---|---|
| Size | ||
| Market cap | ₹31,541 Cr | ₹27,466 Cr |
| Revenue (latest FY) | ₹3,373 Cr | ₹1,754 Cr |
| Net profit (latest FY) | ₹213 Cr | ₹247 Cr |
| Valuation | ||
| P/E | 76.9 | 84.6 |
| P/B | 6.12 | 19.39 |
| Dividend yield | — | 0.00% |
| Profitability | ||
| Return on equity | 7.9% | 22.9% |
| Net profit margin | 10.9% | 15.5% |
| Operating margin | 20.4% | 23.8% |
| Growth | ||
| Revenue growth (YoY) | +23.9% | +39.9% |
| Net profit growth (YoY) | +1.3% | +68.0% |
| Revenue CAGR (multi-year) | +4.5% | — |
| Financial health | ||
| Debt to equity | 0.42 | 0.28 |
| Momentum | ||
| 1-month return | -9.5% | +5.3% |
| 1-year return | +49.0% | +176.3% |
| 3-year CAGR | +102.7% | — |
| 5-year CAGR | +35.5% | — |
| 10-year CAGR | +10.0% | — |
| Distance from 52W high | -16.4% | -10.8% |
| Technicals | ||
| RSI (14) | 49 | 65 |
| Price vs 200-day avg | +13.4% | +35.2% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Wockhardt | Rubicon Research |
|---|---|---|
| Price above 50-day average | ✗ | ✗ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✗ | ✗ |
| Score | 7/10 | 8/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Wockhardt or Rubicon Research?
Wockhardt has a market cap of ₹31,541 Cr and Rubicon Research has a market cap of ₹27,466 Cr as of 06 Nov 2026.
Which has a lower P/E, Wockhardt or Rubicon Research?
Wockhardt has the lower P/E: Wockhardt trades at 76.9 and Rubicon Research at 84.6.
Which gave better returns in the last year, Wockhardt or Rubicon Research?
Rubicon Research did better: Wockhardt returned +49.0% and Rubicon Research returned +176.3% over one year.
Is Wockhardt or Rubicon Research a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Wockhardt scores 7/10 and Rubicon Research scores 8/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.